BACKGROUND: Gene expression profiling (GEP) testing can help to predict the risk of cancer recurrence and guide decisions about adjuvant chemotherapy for breast cancer (BC). However, no prior US studies have evaluated the relation between GEP testing and the use of adjuvant chemotherapy by women treated in a general oncology practice. METHODS: Eligible patients were women under the age 65 of years who were newly diagnosed with their first stage I or II, hormone receptor-positive BC between 2006 and 2011 (n = 9405). This retrospective study was conducted with a data set consisting of registry data, health claims data, and GEP testing results. The distribution of GEP test results was reported in terms of the risk of recurrence predicted, and logistic regression was used to assess the association of test results with chemotherapy use, with adjustments made for multiple patient characteristics. RESULTS: The proportions of tested women with low, intermediate, and high recurrence score results were 51%, 39%, and 10%, respectively. Among these women, 11%, 47%, and 88%, respectively, received adjuvant chemotherapy. There was a significant, positive linear relation of assay scores with chemotherapy use within the low and intermediate subgroups after adjustments for all other factors (adjusted odds ratios, 1.17 and 1.20, respectively). CONCLUSIONS: Adjuvant chemotherapy use after GEP testing is generally consistent with the recommended test interpretation for women with a high or low predicted risk of recurrence. Chemotherapy use in the intermediate-risk group increased with Recurrence Score values, and evidence from ongoing randomized trials may help to clarify whether this finding reflects optimal interpretation of GEP test results. These results demonstrate the principle that genomic testing, on the basis of research establishing its utility, can be applied appropriately in general practice in accordance with guideline recommendations.
BACKGROUND: Gene expression profiling (GEP) testing can help to predict the risk of cancer recurrence and guide decisions about adjuvant chemotherapy for breast cancer (BC). However, no prior US studies have evaluated the relation between GEP testing and the use of adjuvant chemotherapy by women treated in a general oncology practice. METHODS: Eligible patients were women under the age 65 of years who were newly diagnosed with their first stage I or II, hormone receptor-positive BC between 2006 and 2011 (n = 9405). This retrospective study was conducted with a data set consisting of registry data, health claims data, and GEP testing results. The distribution of GEP test results was reported in terms of the risk of recurrence predicted, and logistic regression was used to assess the association of test results with chemotherapy use, with adjustments made for multiple patient characteristics. RESULTS: The proportions of tested women with low, intermediate, and high recurrence score results were 51%, 39%, and 10%, respectively. Among these women, 11%, 47%, and 88%, respectively, received adjuvant chemotherapy. There was a significant, positive linear relation of assay scores with chemotherapy use within the low and intermediate subgroups after adjustments for all other factors (adjusted odds ratios, 1.17 and 1.20, respectively). CONCLUSIONS: Adjuvant chemotherapy use after GEP testing is generally consistent with the recommended test interpretation for women with a high or low predicted risk of recurrence. Chemotherapy use in the intermediate-risk group increased with Recurrence Score values, and evidence from ongoing randomized trials may help to clarify whether this finding reflects optimal interpretation of GEP test results. These results demonstrate the principle that genomic testing, on the basis of research establishing its utility, can be applied appropriately in general practice in accordance with guideline recommendations.
Authors: Mary Jo Lund; Marina Mosunjac; Kelly M Davis; Sheryl Gabram-Mendola; Monica Rizzo; Harvey L Bumpers; Sherita Hearn; Amelia Zelnak; Toncred Styblo; Ruth M O'Regan Journal: Cancer Date: 2011-06-30 Impact factor: 6.860
Authors: Catherine M Kelly; Savitri Krishnamurthy; Giampaolo Bianchini; Jennifer K Litton; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Lajos Pusztai Journal: Cancer Date: 2010-11-15 Impact factor: 6.860
Authors: Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: A J Nixon; D Neuberg; D F Hayes; R Gelman; J L Connolly; S Schnitt; A Abner; A Recht; F Vicini; J R Harris Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: Scott D Ramsey; William E Barlow; Ana M Gonzalez-Angulo; Sean Tunis; Laurence Baker; John Crowley; Patricia Deverka; David Veenstra; Gabriel N Hortobagyi Journal: Contemp Clin Trials Date: 2012-09-18 Impact factor: 2.226
Authors: Leonard R Henry; Alexander Stojadinovic; Sandra M Swain; Sheila Prindiville; Rose Cordes; Peter W Soballe Journal: J Surg Oncol Date: 2009-05-01 Impact factor: 3.454
Authors: Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Young Chandler; Clyde B Schechter; Jinani Jayasekera; Aimee Near; Suzanne C O'Neill; Claudine Isaacs; Charles E Phelps; G Thomas Ray; Tracy A Lieu; Scott Ramsey; Jeanne S Mandelblatt Journal: J Clin Oncol Date: 2018-01-08 Impact factor: 44.544
Authors: Suzanne C O'Neill; Kathryn L Taylor; Jonathan Clapp; Jinani Jayasekera; Claudine Isaacs; Deena Mary Atieh Graham; Stuart L Goldberg; Jeanne Mandelblatt Journal: J Health Commun Date: 2018-08-21
Authors: Allison W Kurian; Irina Bondarenko; Reshma Jagsi; Christopher R Friese; M Chandler McLeod; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Timothy P Hofer; Steven J Katz Journal: J Natl Cancer Inst Date: 2018-05-01 Impact factor: 13.506
Authors: Rosemary D Cress; Yingjia S Chen; Cyllene R Morris; Helen Chew; Kenneth W Kizer Journal: Cancer Causes Control Date: 2016-04-20 Impact factor: 2.506
Authors: Steven J Katz; Timothy P Hofer; Yun Li; Allison W Kurian; Irina Bondarenko; Jeremy M G Taylor; Reshma Jagsi; Kevin C Ward; Ann S Hamilton Journal: Breast Cancer Res Treat Date: 2016-12-23 Impact factor: 4.624
Authors: Christopher R Friese; Yun Li; Irina Bondarenko; Timothy P Hofer; Kevin C Ward; Ann S Hamilton; Dennis Deapen; Allison W Kurian; Steven J Katz Journal: Cancer Date: 2016-10-24 Impact factor: 6.921
Authors: Suzanne C O'Neill; Claudine Isaacs; Filipa Lynce; Deena Mary Atieh Graham; Calvin Chao; Vanessa B Sheppard; Yingjun Zhou; Chunfu Liu; Nandini Selvam; Marc D Schwartz; Arnold L Potosky Journal: Breast Cancer Res Date: 2017-03-31 Impact factor: 6.466
Authors: Benjamin M Parsons; Jeffrey Landercasper; Angela L Smith; Ronald S Go; Andrew J Borgert; Leah L Dietrich Journal: Breast Cancer Res Treat Date: 2016-08-09 Impact factor: 4.872
Authors: Anosheh Afghahi; Maya Mathur; Caroline A Thompson; Aya Mitani; Joseph Rigdon; Manisha Desai; Peter P Yu; Monique A de Bruin; Tina Seto; Cliff Olson; Pragati Kenkare; Scarlett L Gomez; Amar K Das; Harold S Luft; George W Sledge; Amy P Sing; Allison W Kurian Journal: J Oncol Pract Date: 2016-05-24 Impact factor: 3.714